INTRODUCTION {#s1}
============

Prostate cancer (PCa) is the most common cancer in the worldwide and its morbidity,mortality is the first and second common cancer in men, respectively \[[@R1]\]. RP is the standard therapy for patients with localized PCa \[[@R2]\]. However, open retropubic radical prostatectomy (RRP) is associated with higher overall complications, including estimated blood loss (EBL), wound infections. With the development of surgical techniques, laparoscopic techniques and robot assisted surgeries have become a very popular procedure for the management of urological disease throughout the world \[[@R3]\]. Compared with RRP, the advantages of laparoscopic radical prostatectomy (LRP) are less EBL, fewer complications, better cosmetic effect and shorter hospital stay \[[@R4]\]. The disadvantages of LRP is lack of 3D visualization and poor ergonomics.

As alternatives to open surgery, RARP has became a predominant procedure for the treatment the localized prostate cancer in the world \[[@R5]\]. Assessing of the robotic surgery by expert indicate better ergonomics and quicker learning curve, but its shortage is high cost of the robotic surgery system.

In recent years, many experts have reported on comparative study of RARP and open RRP. And some meta-analysis were performed to evaluate the advantages and disadvantages of two approaches, including perioperative outcomes, oncologic outcomes \[[@R5]\]. Their early experience showed that the outcomes of this approach with fewer overall complications, quicker convalescence, and lower EBL and transfusion \[[@R5]--[@R7]\]. However, the outcomes of RARP compared with RRP have not been fully evaluated, and no conclusive results are available. Therefore, a systematic review and meta-analysis of the included published studies was performed to compare RARP with RRP.

RESULTS {#s2}
=======

Characteristics of eligible studies {#s2_1}
-----------------------------------

According to search strategy, the included 78 studies \[[@R4], [@R8]--[@R85]\] assessing RARP *vs*. RRP met the inclusion criteria and were applied to perform this meta-analysis (Figure [1](#F1){ref-type="fig"}). Those studies include forty-three retrospective and thirty-five prospective studies and were listed in Table [1](#T1){ref-type="table"}.

![PRISMA diagram\
The search strategy and number of studies identified for inclusion in this meta-analysis.](oncotarget-08-32237-g001){#F1}

###### Characteristics of included studies

  ------------------------------------------------------------------------------------------------------------------------------------
  First author, year   Country       Study interval   Design          LOE   No.of patients\   Matching/\            Quality score^Δ^
                                                                            RARP/RRP          comparable\*          
  -------------------- ------------- ---------------- --------------- ----- ----------------- --------------------- ------------------
  Ahlering, 2004       USA           2001-2002        Prospective     3b    60/60             1, 2, 3, 4            \*\*\*\*\*

  Bae, 2012            Korea         2008-2011        Retrospective   3b    111/70            1, 2, 3, 4, 5, 6      \*\*\*\*\*\*\*

  Ball, 2006           USA           2000-2005        Prospective     3b    82/135            1, 3, 5, 6            \*\*\*\*\*

  Barocas, 2010        USA           2003-2008        Prospective     3b    1413/491          1, 3, 7               \*\*\*\*\*

  Bolenz, 2010         USA           2003-2008        Retrospective   3b    262/161           1, 2, 3, 4, 6         \*\*\*\*\*\*

  Breyer, 2010         USA           2002-2008        Prospective     3b    293/695           1, 3, 4, 5, 6, 7      \*\*\*\*\*\*\*

  Carlsson, 2010       Sweden        2002-2007        Prospective     3b    1253/485          1, 3, 4, 5,           \*\*\*\*\*

  Chan, 2008           USA           2003-2006        Retrospective   3b    660/340           1, 3, 5, 6            \*\*\*\*\*

  Chino, 2009          USA           2003-2007        Retrospective   3b    368/536           1, 3, 5, 6            \*\*\*\*\*

  Choi, 2012           Korea         2007-2011        Retrospective   3b    354/247           1, 3, 5               \*\*\*\*

  Choo, 2013           Korea         2003-2010        Prospective     3b    77/176            1, 2, 3, 4, 5, 6, 7   \*\*\*\*\*\*\*

  Chung, 2012          Taiwan        2006-2009        Retrospective   4     274/1773          1, 7                  \*\*\*\*

  D\'Alonzo, 2009      USA           2003-2006        Retrospective   3b    256/280           1, 2, 3, 4, 7         \*\*\*\*\*\*

  Di Pierro, 2011      Switzerland   2007-2009        Prospective     3b    75/75             1, 3, 5, 6, 7         \*\*\*\*\*

  Doumerc, 2010        France        2006-2008        Prospective     3b    212/502           1, 3, 4, 5, 6, 7      \*\*\*\*\*\*\*

  Drouin, 2009         France        2000-2004        Retrospective   3b    71/83             1, 2, 3, 5, 6, 7      \*\*\*\*\*\*\*

  Farnham, 2006        USA           2003-2004        Prospective     3b    176/103           1, 3, 4, 6            \*\*\*\*\*

  Ficarra, 2009        Italy         2006-2007        Prospective     3b    103/105           1, 2, 3, 4, 5, 6, 7   \*\*\*\*\*\*\*

  Fracalanza, 2008     Italy         2006             Prospective     3b    35/26             1, 2, 3, 4, 6         \*\*\*\*\*\*

  Forehner, 2013       Germany       2007-2011        Prospective     3b    252/1925          1, 3, 6, 7            \*\*\*\*\*

  Hong, 2010           Korea         2007             Retrospective   4     26/25             1, 2, 7               \*\*\*\*

  Park, 2014           Korea         2007-2012        Retrospective   3b    730/277           1, 2, 3, 4, 5, 6, 7   \*\*\*\*\*\*\*

  Busch, 2015          Germany       NA               Prospective     3b    194/194           1, 3, 5, 6            \*\*\*\*\*

  Kim, 2011            Korea         2007-2010        Prospective     3b    528/235           1, 2, 3, 5, 6, 7      \*\*\*\*\*\*

  Kordan, 2010         USA           2003-2006        Prospective     3b    830/414           1, 2, 3, 5, 6         \*\*\*\*\*

  Krambeck, 2008       USA           2002-2005        Prospective     3b    294/588           1, 2, 3, 5, 6, 7      \*\*\*\*\*\*\*

  Laurila, 2009        USA           2006             Retrospective   3b    94/98             1, 3, 5, 6            \*\*\*\*\*

  Lo, 2010             HongKong      2006-2007        Retrospective   3b    20/20             1, 3, 5, 6, 7         \*\*\*\*\*

  Magheli, 2011        USA           2000-2008        Prospective     3b    522/522           1, 3, 4, 5, 6, 7      \*\*\*\*\*

  Malcolm, 2010        USA           2000-2008        Retrospective   3b    477/135           1, 3, 5, 6, 7         \*\*\*\*\*

  Menon, 2002          France        2001             Prospective     3b    30/30             1, 3, 4, 5, 6, 7      \*\*\*\*\*\*\*

  Miller, 2007         USA           2002-2006        Prospective     4     42/120            1                     \*\*\*\*

  Minniti, 2011        Italy         2007-2008        Prospective     3b    22/93             1, 2, 3, 5            \*\*\*\*

  Nelson, 2007         USA           2003-2006        Prospective     3b    629/374           1, 3, 6               \*\*\*\*\*

  OU, 2009             Taiwan        2004-2007        Retrospective   3b    30/30             1, 2, 3, 4, 5, 6      \*\*\*\*\*\*\*

  Pilecki, 2014        USA           2011             Retrospective   4     4374/1097         1, 2                  \*\*\*\*

  Rocco, 2009          Italy         2004-2007        Prospective     3b    120/240           1, 3, 5, 6, 7         \*\*\*\*\*\*

  Ryu, 2013            Korea         2007-2012        Prospective     4     524/341           1, 2, 3, 4            \*\*\*\*\*

  Schroeck, 2008       USA           2003-2007        Retrospective   3b    362/435           1, 2, 3, 4, 5, 6, 7   \*\*\*\*\*\*\*

  Shapiro, 2014        USA           2000-2010        Retrospective   3b    108/229           1, 3, 5, 6, 7         \*\*\*\*\*

  Silberstein, 2012    USA           2010             Retrospective   4     126/126           1, 3, 5, 6            \*\*\*\*\*

  Smith, 2007          USA           2002-2006        Retrospective   3b    200/200           1, 2, 3, 4, 5, 6      \*\*\*\*\*\*\*

  Son, 2013            Korea         2006-2009        Retrospective   3b    146/112           1, 2, 3, 4, 6, 7      \*\*\*\*\*\*

  Stranne, 2010        Sweden        2002-2006        Retrospective   3b    946/465           1, 2, 3, 4, 5, 6, 7   \*\*\*\*\*\*\*

  Sugihara, 2014       Japan         2012-2013        Retrospective   3b    2126/7202         1, 2, 5,              \*\*\*\*

  Tewari, 2003         USA           1999-2002        Prospective     3b    200/100           1, 2, 3, 4, 5, 6, 7   \*\*\*\*\*\*\*

  Truesdale, 2010      USA           2005-2009        Retrospective   3b    99/217            1, 2, 3, 5, 6         \*\*\*\*\*\*

  Vora, 2013           USA           1997-2010        Retrospective   3b    140/95            1, 3, 5, 6, 7         \*\*\*\*\*

  White, 2009          USA           2005-2008        Retrospective   3b    50/50             1, 3, 5, 6            \*\*\*\*\*

  Williams, 2010       USA           2005-2008        Retrospective   4     604/346           1, 3, 5, 6            \*\*\*\*\*

  Wood, 2007           USA           2003-2005        Prospective     4     165/152           1, 3, 7               \*\*\*\*\*

  Yi, 2010             Korea         2006-2009        Retrospective   3b    153/641           1, 2, 3, 6, 7         \*\*\*\*\*

  Rush, 2015           Canada        2009-2012        Retrospective   3b    331/643           1, 2, 3, 4, 7         \*\*\*\*\*

  Ong, 2015            Australian    2009-2012        Prospective     3b    885/1117          1, 3, 5, 6, 7         \*\*\*\*\*\*

  Porcaro, 2015        Italy         2013             Retrospective   4     108/43            1, 2, 3, 4, 5, 6, 7   \*\*\*\*\*\*\*

  O\'Neil, 2015        USA           2011-2012        Prospective     3b    933/1505          1, 3, 6, 7            \*\*\*\*

  Niklas, 2015         Germany       2003-2010        Retrospective   3b    932/499           1, 2, 3, 4, 5, 6, 7   \*\*\*\*\*\*\*

  Haglind, 2015        Sweden        2008-2011        Prospective     3b    1847/778          1, 2, 3, 5, 6         \*\*\*\*\*\*

  Gagnon, 2014         Canada        NA               Retrospective   3b    200/200           1, 2, 3, 4, 5, 6, 7   \*\*\*\*\*\*

  Davison, 2014        Canada        2007-2009        Prospective     3b    78/73             1, 3, 5               \*\*\*\*\*

  Akand, 2015          Turkey        1999-2012        Retrospective   4     79/50             1, 2, 3, 4, 5, 7      \*\*\*\*\*\*

  Korets, 2014         USA           2007-2012        Retrospective   3b    12746/3398        1, 2, 7               \*\*\*\*\*

  Wallerstedt, 2015    Sweden        NA               Prospective     3b    1847/778          1, 2, 3, 5, 6, 7      \*\*\*\*\*\*

  Hu, 2015             USA           2004-2009        Retrospective   3b    5524/7878         1, 2, 3, 5, 6, 7      \*\*\*\*\*\*

  Davis, 2014          USA           2004-2010        Prospective     3b    27348/13840       1, 7                  \*\*\*\*

  Rithch, 2014         USA           2003-2009        Retrospective   3b    742/237           1, 2, 3, 5, 6, 7      \*\*\*\*\*\*

  Gandaglia, 2014      USA           2008-2009        Retrospective   3b    3476/2439         1, 3, 5, 6, 7         \*\*\*\*\*

  Koo, 2014            Korea         1992-2008        Retrospective   3b    175/175           1, 3, 5, 6, 7         \*\*\*\*\*\*

  Busch, 2014          Germany       NA               Retrospective   3b    110/110           1, 2, 3, 4, 5, 6, 7   \*\*\*\*\*\*\*

  Alemozaffar, 2015    USA           2000-2010        Prospective     3b    282/621           1, 2, 3, 4, 5, 6, 7   \*\*\*\*\*\*\*

  Harty, 2013          USA           2000-2010        Prospective     3b    152/153           1, 3, 4, 5, 6, 7      \*\*\*\*\*\*\*

  Silberstein, 2013    USA           2007-2010        Retrospective   3b    493/961           1, 3, 5, 7            \*\*\*\*\*

  Ludovico, 2013       Italy         2004-2008        Retrospective   3b    82/48             1, 3, 5, 6, 7         \*\*\*\*\*\*

  Musch, 2013          Germany       2009-2010        Retrospective   3b    105/105           1, 2, 3, 4, 5, 6, 7   \*\*\*\*\*\*

  Hall, 2014           Australia     2007-2009        Retrospective   3b    100/100           1, 3, 6               \*\*\*\*\*

  Geraerts, 2013       Belgium       2009-2011        Prospective     3b    64/116            1, 2, 7               \*\*\*\*\*

  Drouin, 2014         France        2007-2010        Prospective     3b    73/44             1, 3, 5, 6, 7         \*\*\*\*\*\*

  Pierorazio, 2013     USA           2002-2011        Retrospective   3b    105/743           1, 2, 3, 4, 5, 6, 7   \*\*\*\*\*\*\*
  ------------------------------------------------------------------------------------------------------------------------------------

RARP=robot-assisted radical prostatectomy; RRP= retropubic radical prostatectomy; NA= data not available; LOE= level of evidence.

\*:Matching/comparable variable: 1=age, 2=BMI, 3=PSA, 4=prostate size, 5=clinical stage, 6= biospy Gleason score, 7=follow up

Δ:based on Newcastle-Ottawa Scale.

Quality of the studies and level of evidence (Table [1](#T1){ref-type="table"})In this meat-analysis, the Newcastle-Ottawa Scale quality assessment method of the observational studies \[[@R86]\], and the US Preventive Services Task Force grading system \[[@R87]\] were applied to evaluate the quality of included studies. Twenty studies scored seven stars and were evaluated as the high quality studies. Additionally, The clinical variables of RARP and RRP were extracted independently from included literatures (Table [1](#T1){ref-type="table"}).

Description of included studies and patients Demographics (Table [2](#T2){ref-type="table"}) {#s2_2}
--------------------------------------------------------------------------------------------

###### Overall analysis of demographic and clinical characteristics compared RARP with RRP

  ----------------------------------------------------------------------------------------------------------------------------------------------
  Outcomes of interest   No. of studies   No. of patients\   OR/WMD(95% CI )        *p*-value     Study heterogeneity              
                                          RARP/RRP                                                                                 
  ---------------------- ---------------- ------------------ ---------------------- ------------- --------------------- ---- ----- -------------
  Age(year)              33               41866/227181       -1.00\[-1.56,-0.44\]   **\<0.001**   1260.51               32   97%   **\<0.001**

  BMI(kg/m^2^)           17               9365/4690          -0.10\[-0.39,0.20\]    0.52          87.93                 16   82%   **\<0.001**

  Pre-PSA(ng/ml)         23               6161/5250          -0.93\[-1.47,-0.40\]   **\<0.001**   234.69                22   91%   **\<0.001**

  Prostate volume(ml)    12               3995/3288          2.35\[-0.92,5.61\]     0.16          136.49                11   92%   **\<0.001**
  ----------------------------------------------------------------------------------------------------------------------------------------------

RARP=robot-assisted radical prostatectomy; RRP=retropubic radical prostatectomy; OR = odds ratio; WMD = weighted mean difference; CI = confidence interval; BMI = body mass index.

Patients underwent RARP are younger (WMD = -1.00 years; 95% CI: -1.56 to -0.44; *P* \< 0.001) ([Figure S1](#SD1){ref-type="supplementary-material"}), and have the lower level of pre-PSA (OR = -0.93; 95% CI: -1.47 to -0.40; *P* \< 0.001) ([Figure S2](#SD1){ref-type="supplementary-material"}). But there is no significant difference on BMI (OR = -0.10; 95% CI: -0.39 to 0.20;*P* = 0.20) ([Figure S3](#SD1){ref-type="supplementary-material"}), and prostate volume (WMD = 2.35ml; 95% CI: -0.92 to 5.61; *P* = 0.16) ([Figure S4](#SD1){ref-type="supplementary-material"}) between the RARP and RRP group. (Table [2](#T2){ref-type="table"}).

Outcomes of perioperative variables (Table [3](#T3){ref-type="table"}) {#s2_3}
----------------------------------------------------------------------

###### Overall analysis of perioperative outcomes comparing RARP with RRP

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Outcome of interest        No. of studies   No.of patients\   OR/WMD(95%CI) ^†^                          *p*-value     Study heterogeneity              
                                              RARP/RRP                                                                                                    
  -------------------------- ---------------- ----------------- ------------------------------------------ ------------- --------------------- ---- ----- -------------
  Operation time, min        18               36296/17965       39.85\[[@R20].[@R95],[@R58].[@R75]\] ^†^   **\<0.001**   2130.01               17   99%   **\<0.001**

  Estimated blood loss, ml   13               3446/2791         -507.67\[-633.21,-382.12\] ^†^             **\<0.001**   390.34                12   97%   **\<0.001**

  Transfusion rate           26               54847/32967       0.13\[0.08,0.21\]                          **\<0.001**   693.85                25   96%   **\<0.001**

  Remove the catheter, day   5                2135/1264         -3.04\[-4.59,-1.49\] ^†^                   **\<0.001**   260.52                4    98%   **\<0.001**

  Hospital stay, day         11               32196/17106       -1.62\[-2.42,-0.82\] ^†^                   **\<0.001**   1517.19               10   99%   **\<0.001**
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------

RARP=robot-assisted radical prostatectomy; RRP=retropubic radical prostatectomy; OR = odds ratio; WMD = weighted mean difference; CI = confidence interval.

### Operating time and estimated blood loss (EBL) {#s2_3_1}

With respect to perioperative variables, pooling data of 18 studies \[[@R21], [@R23], [@R24], [@R26], [@R29], [@R32], [@R34], [@R40], [@R54], [@R59], [@R60], [@R64], [@R70], [@R75], [@R78], [@R81], [@R84], [@R85]\] involving 54261 participants indicated that RARP has longer operative time than RRP (WMD: 39.85 minutes; 95% CI: 20.95 to 58.75; *P* \< 0.001) (Figure [2](#F2){ref-type="fig"}). Pooling data of 13 studies \[[@R10], [@R21], [@R23], [@R29], [@R30], [@R34], [@R40], [@R60], [@R70], [@R75], [@R78], [@R84], [@R85]\] results showed that RARP has less intraoperative blood loss (WMD = -507.67ml; 95% CI: -633.21 to -382.12; *P* \< 0.001) (Figure [3](#F3){ref-type="fig"}).

![Forest plot and meta-analysis of operating time between RARP and RRP\
RARP = robot-assisted radical prostatectomy; RRP = retropubic radical prostatectomy.](oncotarget-08-32237-g002){#F2}

![Forest plot and meta-analysis of estimated blood loss between RARP and RRP\
RARP = robot-assisted radical prostatectomy; RRP = retropubic radical prostatectomy.](oncotarget-08-32237-g003){#F3}

### Transfusion rate and postoperative recovery {#s2_3_2}

Pooled data from the 26 studies \[[@R9], [@R10], [@R14], [@R21], [@R23], [@R24], [@R26], [@R29], [@R30], [@R34], [@R35], [@R40], [@R44]-[@R46], [@R54], [@R59], [@R64], [@R72], [@R73], [@R78], [@R80], [@R82], [@R84]\] reported transfusion rate between RARP and RRP, and the results showed that RARP was associated with lower transfusion rate (OR = 0.13; 95% CI: 0.08 to 0.21;*P* \< 0.001) than RRP (Figure [4](#F4){ref-type="fig"}). Pooling data of 5 studies reported on the time to remove catheter, the forest plot showed that RARP had shorter time to remove catheter than RRP group (WMD = -3.04; 95% CI: -4.59 to -1.49; *P* \< 0.001) ([Figure S5](#SD1){ref-type="supplementary-material"}). And pooling date of 11 studies \[[@R10], [@R23], [@R24], [@R34], [@R53], [@R54], [@R64], [@R75], [@R78]\] reported on length of hospital stay (LOS), the forest plot showed that RARP had a shorter LOS than RRP (WMD = -1.62; 95% CI: -2.42 to -0.82; *P* \< 0.001) (Figure [5](#F5){ref-type="fig"}).

![Forest plot and meta-analysis of transfusion rate between RARP and RRP\
RARP = robot-assisted radical prostatectomy; RRP = retropubic radical prostatectomy.](oncotarget-08-32237-g004){#F4}

![Forest plot and meta-analysis of the length of hospital stay between RARP and RRP\
RARP = robot-assisted radical prostatectomy; RRP = retropubic radical prostatectomy.](oncotarget-08-32237-g005){#F5}

Outcomes of oncological variables {#s2_4}
---------------------------------

### pathologic stage and pathologic Gleason score (Table [5](#T5){ref-type="table"}) {#s2_4_1}

###### Overall analysis of complications comparing RARP and RRP

  ------------------------------------------------------------------------------------------------------------------------------------------------
  Outcome of interest        No. of studies   No.of patients\   OR (95%CI)            *p*-value     Study heterogeneity              
                                              RARP/RRP                                                                               
  -------------------------- ---------------- ----------------- --------------------- ------------- --------------------- ---- ----- -------------
  Overall complications      25               43087/28834       0.43 \[0.32, 0.58\]   **\<0.001**   499.59                24   95%   **\<0.001**

  Rectal injury              8                3888/8110         0.16\[0.07, 0.39\]    **\<0.001**   5.22                  7    0%    0.63

  Pulmonary embolism         9                37575/24635       0.47\[0.37, 0.59\]    **\<0.001**   5.04                  8    0%    0.75

  Wound infections           10               11161/10587       0.23\[0.11, 0.46\]    **\<0.001**   31.49                 9    71%   **\<0.001**

  Bladder neck contracture   4                1993/2409         0.21\[0.08,0.60\]     **0.003**     8.39                  3    64%   **0.04**

  UTI                        4                6586/2546         0.75\[0.37,1.54\]     0.44          15.35                 3    80%   **0.002**

  Urinary retention          3                2042/960          0.63\[0.47,0.84\]     **0.002**     2.44                  2    18%   0.29

  Obturator nerve injury     2                1453/585          0.09\[0.01,0.75\]     **0.03**      0.01                  1    0%    0.91

  DVT                        7                7479/3072         0.40\[0.25,0.66\]     **\<0.001**   10.82                 6    45%   0.09

  Urinary leakage            8                30940/15631       0.64\[0.58,0.70\]     **\<0.001**   8.87                  7    21%   0.26

  ileus                      8                3412/8501         0.92\[0.56,1.51\]     0.73          2.20                  7    0%    0.95

  lymphocele                 9                45258/2639        0.52\[0.29,0.94\]     **0.03**      8.93                  8    10%   0.35

  Urinary continence-3mo     9                997/941           1.54\[0.92,2.58\]     0.10          22.06                 8    64%   **0.005**

  Urinary continence-12mo    9                1565/2179         1.03\[0.84,1.27\]     0.75          17.41                 8    54%   0.03

  Potent recovery-3mo        5                1169/820          3.19\[1.19,8.56\]     **0.02**      51.94                 4    92%   **\<0.001**

  Potent recovery-12mo       7                1395/1574         2.37\[1.30,4.33\]     **0.005**     55.43                 6    89%   **\<0.001**

  Readmission rate           7                11632/7060        0.83\[0.74,0.94\]     **0.002**     36.82                 6    84%   **\<0.001**
  ------------------------------------------------------------------------------------------------------------------------------------------------

RARP=robot-assisted radical prostatectomy; RRP= retropubic radical prostatectomy; OR = odds ratio; WMD = weighted mean difference; CI = confidence interval; UTI=urinary tract infection; DVT=deep venous thrombosis.

###### Overall analysis of pathologic and oncological outcomes comparing RARP with RRP

  ---------------------------------------------------------------------------------------------------------------------------------------------------------
  Outcome of interest              No. of studies   No.of patients\   OR/WMD(95%CI)            *p*-value     Study heterogeneity              
                                                    RARP/RRP                                                                                  
  -------------------------------- ---------------- ----------------- ------------------------ ------------- --------------------- ---- ----- -------------
  **Pathologic T stage**                                                                                                                      

  ≤pT2a                            13               2147/2174         1.11\[0.93,1.31\]        0.26          8.84                  12   0%    0.72

  pT2b                             11               1959/2098         1.11\[0.93,1.33\]        0.25          13.91                 10   28%   0.18

  ≥pT2c                            14               2268/2485         0.93\[0.76,1.13\]        0.44          11.19                 13   0%    0.60

  **Pathological Gleason score**                                                                                                              

  ≤6                               48               15238/13412       1.04\[0.91,1.18\]        0.61          224.21                47   79%   \<0.001

  7                                48               15238/13412       1.17\[1.04,1.33\]        **0.01**      230.23                47   80%   \<0.001

  ≥8                               48               15238/13412       0.68\[0.60,0.78\]        **\<0.001**   101.358               47   54%   \<0.001

  PSM                              49               20804/23133       0.88\[0.78,1.00\]        **0.04**      198.74                48   76%   \<0.001

  PSM for T2                       28               10086/9711        0.77\[0.63,0.95\]        **0.01**      82.23                 27   67%   **\<0.001**

  PSM for T3                       18               2011/2125         1.46\[1.27,1.67\]        **\<0.001**   18.66                 17   9%    0.35

  Mean lymph node yield            4                837/565           2.85\[-0.92,6.63\] ^†^   0.14          115.32                3    97%   **\<0.001**

  Positive lymph node              16               4162/6500         0.45\[0.31,0.65\]        **\<0.001**   32.02                 15   53%   0.006

  BCR for free survival            10               4342/4176         1.33\[1.01,1.76\]        **0.04**      39.04                 9    77%   **\<0.001**
  ---------------------------------------------------------------------------------------------------------------------------------------------------------

RARP=robot-assisted radical prostatectomy; RRP=retropubic radical prostatectomy; OR = odds ratio; WMD = weighted mean difference; CI = confidence interval; PSM=positive surgical margins; ^†^value of WMD.

14 studies \[[@R9], [@R20], [@R27]-[@R29], [@R32], [@R46], [@R48], [@R66], [@R70], [@R73], [@R76], [@R77], [@R80]\] on ≤pT2a, pT2b, ≥pT2c, 48 studies \[[@R8]-[@R13], [@R15], [@R16], [@R18], [@R19], [@R21], [@R26]-[@R29], [@R31], [@R32], [@R34], [@R42]-[@R44], [@R46]-[@R50], [@R52], [@R54], [@R55], [@R57], [@R58], [@R60], [@R61], [@R64]-[@R71], [@R73], [@R74], [@R76]-[@R78], [@R82], [@R85]\] on pathologic Gleason score (≤6; 7; ≥8) were reported, respectively. The results showed a statistical differences more Gleason score = 7 (OR: 1.17; 95% CI: 1.04 to 1.33; *P* = 0.01; Figure [6](#F6){ref-type="fig"}) performed RARP and more Gleason score ≥8 (OR: 0.68; 95% CI: 0.60 to 0.78; *P* \< 0.001; Figure [6](#F6){ref-type="fig"}) in RRP. However, there were no statistical differences with respect to Gleason score≤6 (OR: 1.04; 95% CI: 0.91 to 1.18; *P* = 0.61; Figure [6](#F6){ref-type="fig"}) and pathologic T stage in the two groups ([Figure S6](#SD1){ref-type="supplementary-material"},[7](#SD1){ref-type="supplementary-material"},[8](#SD1){ref-type="supplementary-material"})(Table [5](#T5){ref-type="table"}).

![Forest plot and meta-analysis of pathological Gleason Score between RARP and RRP\
RARP = robot-assisted radical prostatectomy; RRP = retropubic radical prostatectomy.](oncotarget-08-32237-g006){#F6}

### Positive surgical margins and lymph node yield(Table [5](#T5){ref-type="table"}) {#s2_4_2}

49 studies \[[@R9]-[@R12], [@R14]-[@R16], [@R18], [@R19], [@R21], [@R26]-[@R29], [@R31]-[@R34], [@R36], [@R37], [@R39], [@R41]-[@R44], [@R46]-[@R49], [@R52], [@R54], [@R56]-[@R58], [@R61], [@R62], [@R65], [@R67]-[@R69], [@R73], [@R76]-[@R78], [@R80]-[@R82], [@R84]\] evaluating RARP and RRP reported positive surgical margins(PSM) rates. The results showed a significant difference with higher PSM rates in RRP group (OR:0.88; 95% CI: 0.78 to 1.00; *P* = 0.04)(Figure [7](#F7){ref-type="fig"}). PSM rates in pT3 cancers was higher in RARP group (OR:1.46; 95% CI: 1.27 to 1.67; *P* \< 0.001) (Figure [8](#F8){ref-type="fig"}). However, the results showed that PSM rates in pT2 cancers was lower in RARP (OR:0.77; 95% CI: 0.63 to 0.95; *P* = 0.01)(Figure [9](#F9){ref-type="fig"}). Four studies \[[@R20], [@R43], [@R60], [@R73]\] comparing mean lymph node yield and the results showed that lymph node yield is higher in RARP (WMD: 1.61; 95% CI: 1.18 to 2.05; *P* \< 0.001)([Figure S9](#SD1){ref-type="supplementary-material"}), and 16 studies \[[@R20], [@R26], [@R33], [@R34], [@R39], [@R49], [@R58], [@R61], [@R64]-[@R68], [@R73], [@R84], [@R85]\] reported on positive lymph node, There was a statistical differences decreased positive lymph node in RARP than RRP (OR:0.45; 95% CI: 0.31 to 0.65; *P* \< 0.001)(Figure [10](#F10){ref-type="fig"}).

![Forest plot and meta-analysis of PSM between RARP and RRP\
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![Forest plot and meta-analysis of PSM for pT3 between RARP and RRP\
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![Forest plot and meta-analysis of PSM for pT2 between RARP and RRP\
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![Forest plot and meta-analysis of positive lymph node between RARP and RRP\
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Outcomes of complications(Table [4](#T4){ref-type="table"}) {#s2_5}
-----------------------------------------------------------

Pooling data from 25 studies \[[@R9], [@R11], [@R17], [@R23], [@R24], [@R26], [@R27], [@R29], [@R31], [@R34], [@R35], [@R40], [@R42], [@R46], [@R48], [@R52]-[@R54], [@R59], [@R64], [@R72], [@R73], [@R80], [@R82], [@R84]\] reported on overall complications, RARP had lower overall complications in the RARP than RRP(OR:0.43; 95% CI: 0.32 to 0.58; *P* \< 0.001)(Figure [11](#F11){ref-type="fig"}). Next, a meticulous classification of overall complications showed that RRP had a higher incidence of rectal injury(OR:0.16; 95% CI: 0.07 to 0.39; *P* \< 0.001)([Figure S10](#SD1){ref-type="supplementary-material"}), pulmonary embolism(OR:0.47; 95% CI: 0.37 to 0.59; *P* \< 0.001) ([Figure S11](#SD1){ref-type="supplementary-material"}), wound infections (OR:0.23; 95% CI: 0.11 to 0.46; *P* \< 0.001) ([Figure S12](#SD1){ref-type="supplementary-material"}), bladder neck contracture(OR: 0.21; 95% CI: 0.08 to 0.60; *P* = 0.003) ([Figure S13](#SD1){ref-type="supplementary-material"}), urinary retention(OR:0.63; 95% CI: 0.47 to 0.84; *P* = 0.002)([Figure S14](#SD1){ref-type="supplementary-material"}), deep venous thrombosis(OR:0.40; 95% CI: 0.25 to 0.66; *P* \< 0.001) ([Figure S15](#SD1){ref-type="supplementary-material"}), urinary leakage(OR: 0.64; 95% CI: 0.58 to 0.70; *P* \< 0.001) ([Figure S16](#SD1){ref-type="supplementary-material"}), lymphocele (OR:0.52; 95% CI: 0.29 to 0.94; *P* = 0.03) ([Figure S17](#SD1){ref-type="supplementary-material"}), and obturator nerve injury(OR:0.09; 95% CI: 0.01 to 0.75; *P* = 0.03) ([Figure S18](#SD1){ref-type="supplementary-material"}). There was no statistical differences between two groups in term of urinary tract infections(UTI)(OR:0.75; 95% CI: 0.37 to 1.54; *P* = 0.44)([Figure S19](#SD1){ref-type="supplementary-material"}), ileus (OR:0.92; 95% CI: 0.56 to 1.51; *P* = 0.73) ([Figure S20](#SD1){ref-type="supplementary-material"}).

![Forest plot and meta-analysis of overall complications between RARP and RRP\
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### Urinary continence recovery and potent recovery(Table [4](#T4){ref-type="table"}) {#s2_5_1}

Pooling data of 9 studies \[[@R9], [@R21], [@R26], [@R50], [@R62], [@R70], [@R81], [@R83], [@R84]\] reported on 3-mo and 12-mo urinary continence recovery between two groups. The forest plot showed that there were no statistical differences on the 3-mo and 12-mo urinary continence between two groups (3mo: OR:1.54; 95% CI: 0.92 to 2.58; *P* = 0.10; 12mo: OR:1.03; 95% CI: 0.84 to 1.27; *P* = 0.75,respectively)(Figure [12](#F12){ref-type="fig"}, [Figure S21](#SD1){ref-type="supplementary-material"}). And the 3- and 12-mo potent recovery rate of RARP were better than RRP group, respectively (OR:3.19; 95% CI: 1.19 to 8.56; *P* = 0.02; OR: 2.37; 95% CI: 1.30 to 4.33; *P* = 0.005,respectively)(Figures [13](#F13){ref-type="fig"},[14](#F14){ref-type="fig"}).

![Forest plot and meta-analysis of 3-mo urinary continence rate between RARP and RRP\
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![Forest plot and meta-analysis of 3-mo potent recovery rate between RARP and RRP\
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![Forest plot and meta-analysis of 12-mo potent recovery rate between RARP and RRP\
RARP = robot-assisted radical prostatectomy; RRP = retropubic radical prostatectomy.](oncotarget-08-32237-g014){#F14}

### Biochemical recurrence free survival and Readmission rate(Table [5](#T5){ref-type="table"}) {#s2_5_2}

Pooling data from 10 studies \[[@R12], [@R16], [@R34], [@R49], [@R56], [@R61], [@R65]-[@R67], [@R74]\] reported on biochemical recurrence(BCR) free survival, these results showed that RARP had a better BCR free survival than RRP(OR:1.33; 95% CI: 1.01 to 1.76; *P* = 0.04) (Figure [15](#F15){ref-type="fig"}). Pooling data from 7 studies \[[@R22], [@R35], [@R38], [@R53], [@R54], [@R59], [@R75]\] reported on readmission rate, the forest plot showed that RARP had a lower readmission rate than RRP(OR:0.83; 95% CI: 0.74 to 0.94; *P* = 0.002) (Figure [16](#F16){ref-type="fig"}).

![Forest plot and meta-analysis of BCR free survival rate between RARP and RRP\
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![Forest plot and meta-analysis of readmission rate between RARP and RRP\
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Sensitivity analysis {#s2_6}
--------------------

42 qualified studies with patients' baseline characteristic consistency(age, pre-PSA, BMI, prostate volume, *P* \> 0.5) are analyzed by sensitivity analysis (Table [6](#T6){ref-type="table"}). Compared with the original analysis, there was no change in the significance of any other outcomes except that readmission rate(*P* = 0.002 *vs* *P* = 0.13), and BCR for free survival(*P =* 0.04 *vs*. *P* = 0.55) were significantly different in sensitivity analysis. The method of sensitivity analysis can reduce the heterogeneity of studies to a certain extent.

###### Sensitivity analysis of high quality studies comparing RARP with RRP

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Outcome of interest              No. of studies   No.of patients\   OR/WMD(95%CI) ^†^                *p*-value     Study heterogeneity              
                                                    RARP/RRP                                                                                          
  -------------------------------- ---------------- ----------------- -------------------------------- ------------- --------------------- ---- ----- --------------
  Operation time, min              10               1523/1435         44.43\[8.01,80.84\] ^†^          **0.02**      1166.56               9    99%   **\<0.0001**

  Estimated blood loss, ml         8                1080/1102         -493.41\[-672.09,-314.74\] ^†^   **\<0.001**   217.36                7    97%   **\<0.0001**

  Transfusion rate                 18               16249/7209        0.16\[0.09,0.28\]                **\<0.001**   116.44                17   85%   **\<0.0001**

  Remove the catheter, day         3                1173/735          -1.78\[-2.50,-1.06\] ^†^         **\<0.001**   19.52                 2    90%   **\<0.0001**

  Hospital stay, day               6                1568/1117         -0.75\[-1.26,-0.24\] ^†^         **0.004**     75.72                 5    93%   **\<0.0001**

  Overall complications            14               2782/2767         0.50 \[0.27, 0.92\]              **0.03**      158.13                13   92%   **\<0.0001**

  Urinary continence-3mo           7                945/818           1.21\[0.74,1.98\]                0.45          13.33                 6    55%   **0.04**

  Urinary continence-12mo          4                942/1409          0.97\[0.78,1.20\]                0.79          10.89                 6    45%   0.09

  Potent recovery-3mo              4                722/685           4.50\[1.91,10.62\]               **\<0.001**   17.64                 3    83%   **\<0.001**

  Potent recovery-12mo             4                942/1409          1.58\[1.05,2.36\]                **0.03**      10.33                 3    71%   **0.02**

  Readmission rate                 4                2850/3025         0.53\[0.23,1.21\]                0.13          24.10                 3    88%   **\<0.001**

  **Pathologic T stage**                                                                                                                              

  ≤pT2a                            10               1725/1871         1.02\[0.83,1.26\]                0.83          7.02                  9    0%    0.63

  pT2b                             9                1675/1821         0.99\[0.80,1.21\]                0.90          8.07                  8    1%    0.43

  ≥pT2c                            12               1979/2212         0.98\[0.79,1.21\]                0.84          9.48                  11   0%    0.58

  **Pathological Gleason score**                                                                                                                      

  ≤6                               27               5847/6576         0.99\[0.87,1.13\]                0.88          45.37                 26   43%   0.01

  7                                27               5847/6576         1.14\[1.02,1.28\]                **0.02**      46.80                 26   44%   0.007

  ≥8                               27               5847/6576         0.79\[0.67,0.92\]                **0.003**     38.31                 26   32%   0.06

  PSM                              39               13992/17806       0.87\[0.76,0.99\]                **0.04**      123.38                37   70%   **\<0.001**

  PSM for T2                       16               6649/7986         0.71\[0.53,0.95\]                **0.02**      51.53                 15   71%   **\<0.001**

  PSM for T3                       12               1423/1713         1.39\[1.19,1.63\]                **\<0.001**   9.38                  11   0%    0.59

  Mean lymph node yield            2                375/275           3.77\[-5.87,13.41\] ^†^          **0.44**      106.54                1    99%   **\<0.001**

  Positive lymph node              10               2668/3684         0.69\[0.52,0.90\]                **0.006**     9.31                  9    3%    0.41

  BCR for free survival            5                1192/1797         1.16\[0.71,1.89\]                **0.55**      23.76                 4    83%   **\<0.001**
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------

RARP=robot-assisted radical prostatectomy; RRP=retropubic radical prostatectomy; OR = odds ratio; WMD = weighted mean difference; CI = confidence interval.

DISCUSSION {#s3}
==========

The incidence of prostate cancer and its mortality is the first and the second common cancer in man, respectively \[[@R1]\]. Our results indicated that RARP seemed to have an younger age (WMD: -1.00; *P* \< 0.001), and to have the lower level of pre-PSA (WMD: -0.93; *P* \< 0.001) than RRP group, and that these differences are primarily due to surgeon\'s preference for surgical modality. Another reason is that the younger is more easier to choose new approach. However, there is no difference on BMI and prostate volume between the two groups. Sensitivity analysis showed that there was no change in the significance of any other outcomes except that readmission rate(*P* = 0.002 *vs* *P* = 0.13) and BCR for free survival(*P =* 0.04 *vs*. *P* = 0.55).It demonstrated that selection bias of demographic and clinical data of patients is small between two groups.

Novara G et al \[[@R6]\] evaluated oncologic outcomes of RARP and RRP, and the results indicated that RARP had less EBL and transfusion rate than RRP. Their results presented similar results and strengthened our results. The other analyzed parameters operative time and complication rate were similar. However, in our meta-analysis, RARP had longer operative time than RRP(WMD:39.85min, *P*\<0.001), which likely reflects the early learning curve with RARP. But the learning curve indicated that operative time was decreased with growing operative experience and it won\'t influenced operative outcomes \[[@R88]\].

With regard to the pathologic outcomes, patients underwent RARP had more pathological Gleason score = 7, less pathological Gleason score ≥8, higher lymph node yield and fewer positive lymph node than RRP. However, the pathological T stage is no significant difference between the RARP and RRP group. LN yield was deemed an indicator of surgical quality by many surgeons \[[@R89]\]. RARP had a higher LN yield than RRP, the reason is that RARP has meticulous dissection with 3D vision and decrease the intraoperative blood loss which made the surgeon have more time and patience to acquiring higher LN yield. Therefore, the oncological outcomes in terms of PSM for T3 is higher in RARP than RRP. With the results that BCR free survival was higher in RARP than RRP. Some studies showed that the predictors of BCR were preoperative PSA. Gleason score, pathological stage, and PSM \[[@R49]\].

The experts suggested that patient outcomes and surgical approach were mainly required to improve for an accurate characterization of complications \[[@R90]\]. In our meta-analysis, Patients underwent RARP had fewer overall complications than RRP. The possible reason may be associated with lower EBL and less transfusion rate in RARP. Then a comprehensive classification of complications indicated that RRP had a higher incidence of rectal injury, pulmonary embolism, wound infections, bladder neck contracture, urinary retention, deep venous thrombosis, urinary leakage, lymphocele, and obturator nerve injury. There were no significant differences with regard to ileus and UTI between two groups.

Ficarra V et al \[[@R91]\] compared RARP with RRP with respect to 12-mo urinary continence. Their results indicated that RARP had a better 12-mo urinary continence recovery than RRP(OR:1.53; *P* = 0.03). However, our results indicated that there were no statistical differences with regard to 3-mo and 12-mo urinary continence in two groups. The urinary continence receiving RP is influenced by preoperative patient characteristics, surgical techniques, and so on. Some studies found that patient age \[[@R92], [@R93]\], BMI \[[@R94]\], comorbidity index \[[@R95]\], and prostate volume \[[@R96], [@R97]\] were also the potential predictors of urinary incontinence. Increasing age, higher BMI, and large prostate volume are correlated with high risk of urinary incontinence who underwent RP. However, the 3- and 12-mo potent recovery rate of RARP was also better than RRP group, respectively. Analysis of predictors indicated that peroperative parameters might influence potency results. Relevant predictors included age at surgery, baseline erectile function, and comorbidities \[[@R98]\]. Other authors also confirmed that age and baseline erectile function of patients were affected the potent recovery in nerve-sparing RARP \[[@R93], [@R99]\].

On the other hand, we found better BCR free survival and lower readmission rate in RARP group in the original analysis. The reason is that meticulous dissection, lower blood loss and complications might provide patients better oncologic prognosis in RARP group. However, we observed no statistical differences between RARP and RRP in sensitivity analysis. Therefore, multicenter, large sample, long follow-up RCTs are required to prove our findings.

Nevertheless, there were several limitations when analyzing and interpreting results in our meta-analysis. The major limitation is lack of well designed prospective, randomized control studies in our meta-analysis. Secondly, there existed heterogeneities of studies, especially in the comparing of the continuous data such as the length of hospital stay, operative time. whereas these parameters were influenced by the heterogeneities of patients' conditions, surgeon\'s surgical skills and the sample size of studies. In addition, short follow-up duration may have an influence on the confidence of outcomes. In the future, well-designed, prospective, multicenter randomized control studies are required to help us better demonstrate the advantages as well as drawbacks of this novel approach.

MATERIALS AND METHODS {#s4}
=====================

Literature search strategy {#s4_1}
--------------------------

To update previous systematic review \[[@R5]-[@R7], [@R91], [@R98], [@R100], [@R101]\], a systematic review of published literature was performed according to the Cochrane Handbook recommendations \[[@R102]\]. No ethic issues get involved in this article. A systematic dissertion was conducted using Medline, Embase, Pubmed, CNKI, and all relevant studies had been identified by the Cochrane Library. The following key words were used: "comparative studies", "retropubic", "open", "radical prostatectomy ", "Da Vinci", "robot-assisted", and "prostate cancer".

Data extraction and outcomes of interest {#s4_2}
----------------------------------------

Two of the authors(JKH and TK) extracted data from the selected studies including: author identification, country, publication year, study design, age, No. of patients, operative approaches were mentioned previously, and results of intervention. All disagreements about eligibility were reached a consensus through authors discussion. Perioperative outcomes including operative time, EBL, LOS, overall complications, and oncological outcomes were compared between the two methods from all the studies that were finally selected. Overall complications were graded on the basis of the Clavien-Dindo system \[[@R103]\].

Inclusion criteria and exclusion criteria {#s4_3}
-----------------------------------------

Studies should satisfy the following requirements: (1) to compare RARP with RRP, (2) to display on outcome of two approaches, (3) to document the surgery as RARP or RRP, (4) to clearly document indications for prostatectomy with prostate cancer. Studies will be excluded if (1) the study was not satisfied inclusion criteria or (2) the outcomes of literature were not mentioned or the parameters were impossible to analysis for either RARP or RRP from the published findings and (3) studies focusing on pure robot surgery system and/or on single-site techniques.

Study quality assessment and level of evidence {#s4_4}
----------------------------------------------

In accordance with the criteria of Centre for Evidence-Based Medicine in Oxford, we evaluated the level of evidence(LOE) of included sixteen studies. The Jaded Score was applied to evaluated the methodological quality of RCTs \[[@R104]\]. The Newcastle-Ottawa Scale(NOS) was applied to assessed the methodological quality of non-RCTs observational studies \[[@R86], [@R105]\]. Two authors(JKH and TK) evaluated the quality of the studies and discrepancies were rechecked by the third reviewer(CZQ) and consensus was achieved by discussion.

Statistical analysis {#s4_5}
--------------------

All meta-analysis were conducted by Review Manger 5.3(Cochrane Collaboration, Oxford, UK). Continuous and dichotomous variables were calculated by weighted mean differences (WMDs) and odds ratios(ORs). All analysis results were reported with 95% confidence intervals(CIs). I^2^ test and chi-square-based Q test were applied to evaluated the quantity of heterogeneity, and when I^2^ \> 50%, the evidence was considered to have substantial heterogeneity, the random- effects(RE) model would be applied, otherwise, the fixed effects(FE) model was applied. The presence of publication bias was evaluated by Egger\'s test and funnel plot. Sensitivity analysis was used to estimate the influence of studies with a high risk of bias on the overall effect.

SUPPLEMENTARY MATERIALS TABLES {#s5}
==============================
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